JP
Therapeutic Areas
CoA Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BBP-671 | Pantothenate Kinase-Associated Neurodegeneration (PKAN) | Phase 1 |
Leadership Team at CoA Therapeutics
CS
Christine Siu
Chief Executive Officer, in Residence
US
Uma Sinha, Ph.D.
Chief Scientific Officer
AW
Anna Wade, Ph.D.
Chief Operating Officer
A'
Agnieszka 'AJ' Jurecka, M.D., Ph.D.
Vice President, Clinical Development
NK
Neil Kumar, Ph.D.
Board of Directors